Skip to main content
. 2017 Oct 30;15(1):473–478. doi: 10.3892/etm.2017.5401

Figure 2.

Figure 2.

Expression of miR-503 in prostate cancer tissues and tumor-adjacent normal tissues. (A) Bioinformatics prediction of direct interactions between miR-503 and TPD52L2 using TargetScan. (B) Expression of miR-503 as determined by reverse transcription quantitative polymerase chain reaction. **P<0.01 vs. control. miR-503, microRNA-503; TPD52L2, tumor protein D52 like 2.